CT ABDOMEN CONTRAST AND ABDOMEN TRIPLE PHASE

Reading File
Finding Sources
Finding Sources
Searching the Web

CT abdomen triple phase contrast technique phases clinical indications 2024

Finding Sources
Finding Sources
Reading Web Page

https://litfl.com/abdominal-ct-phases

Reading File
Reading File
Finding Sources
Reading File
Reading File
Here is a thorough overview of CT Abdomen with Contrast and CT Abdomen Triple Phase, synthesized from textbook sources (Grainger & Allison's Diagnostic Radiology, Fischer's Mastery of Surgery, Sabiston, LITFL) and current radiology guidelines.

CT Abdomen with Contrast

Overview

CT abdomen with intravenous (IV) contrast is the most widely used abdominal CT protocol. It provides excellent depiction of solid organs, bowel, vasculature, peritoneum, and retroperitoneum, with contrast dramatically improving lesion-to-background differentiation.

Phases of Enhancement

All contrast phases occur within the first ~1.5 minutes after injection. The key phases are:
PhaseTiming (after IV injection)What is Best Seen
Non-contrastBefore contrastCalcification, hemorrhage, calculi, baseline density
Arterial phase20-35 secondsAorta, hepatic artery, hypervascular lesions, active bleeding
Portal venous phase70-80 secondsPortal vein, hepatic veins, solid organs (liver, spleen, kidneys), bowel
Delayed / Equilibrium phase2-5 minutesFibrotic lesions (cholangiocarcinoma), hemangioma fill-in, urothelium

Portal Venous Phase - The Standard Phase

  • The most commonly used single phase for general abdominal CT
  • Gives the best balance of solid organ, bowel, and vascular enhancement
  • Used for most oncology staging and surveillance, peritoneal disease, and bowel pathology

Arterial Phase

  • Obtained ~20-35 seconds after injection
  • Ideal for: aortic pathology (dissection, aneurysm), active GI bleeding, hypervascular tumors (HCC, neuroendocrine tumors, RCC)

CT Abdomen Triple Phase

Definition

Triple phase CT involves three distinct contrast-enhanced acquisitions at timed intervals to characterize lesion vascularity and enhancement patterns. The classic liver triple phase consists of:
  1. Late arterial phase - 15-30 seconds post bolus trigger (~35-45 s after injection)
  2. Portal venous phase - 60-75 seconds post injection
  3. Delayed phase - 2-5 minutes post injection
Note: Some centers add a non-contrast phase making it a "four-phase" study. The term "triple phase" strictly refers to three post-contrast phases.

Technique (Standard Protocol)

ParameterValue
Patient positionSupine, arms above head
Scan extentDiaphragm to iliac crests
Contrast volume100-120 mL non-ionic iodinated contrast
Injection rate3-5 mL/sec (higher rate = greater enhancement)
Bolus trackingROI in aorta at level of diaphragm; threshold ~150 HU
Slice thickness≤5 mm
RespirationInspiration breath-hold
Pre-scan requirements6-hour fast, serum creatinine/eGFR, allergy/drug history
Contrast dose: 2 mL/kg (maximum 150 mL); non-ionic contrast with 18-20 gauge IV cannula.

Primary Indications

Liver Triple Phase

  • Hepatocellular carcinoma (HCC) - the primary indication
  • Focal nodular hyperplasia (FNH)
  • Hepatic adenoma
  • Hemangioma
  • Hypervascular metastases (neuroendocrine, RCC, melanoma)
  • Cholangiocarcinoma

Pancreas Protocol (also triple/multiphase)

  • Pancreatic ductal adenocarcinoma (PDAC) - staging and resectability
  • Pancreatic neuroendocrine tumors (PNETs)

Other Indications

  • Adrenal lesion characterization
  • Renal mass evaluation
  • GI bleeding (non-contrast + arterial + portal venous)
  • Acute aortic pathology

Phase-Specific Findings in Key Conditions

HCC (Hepatocellular Carcinoma)

The classic hallmark on triple phase CT is:
  • Arterial phase: hyperenhancement (HCC is fed by hepatic artery, not portal vein)
  • Portal venous / delayed phase: "washout" - lesion becomes hypoattenuating relative to liver
  • Pseudocapsule: enhancing rim on delayed phase
Sensitivity and specificity approach 90% for lesions >2 cm on multiphase CT/MRI. This characteristic enhancement pattern is so specific that HCC ≥2 cm can be diagnosed on imaging alone without biopsy, per LI-RADS criteria.
"On contrast-enhanced CT, lesions at least 2 cm in size displaying arterial enhancement, washout on delayed venous phases, and a pseudocapsule are characteristic of HCC." - Fischer's Mastery of Surgery, 8th ed.

Cholangiocarcinoma (vs HCC)

  • Shows progressive enhancement: increasing contrast uptake through venous and delayed phases
  • Opposite pattern to HCC (which shows washout)

Hemangioma

  • Nodular peripheral enhancement in arterial phase
  • Progressive fill-in toward center in portal venous and delayed phases
  • On delayed phase, becomes isodense or hyperdense to liver (complete fill-in)

Pancreatic Cancer (PDAC)

The pancreas/late arterial phase (~45 seconds) is the key phase:
  • PDAC appears hypoattenuating (dark) due to dense desmoplastic stromal reaction
  • Normal pancreas enhances brightly, making the tumor stand out
  • Portal venous phase (~60-70 s) assesses: SMV/PV involvement, hepatic metastases, adenopathy
"The next phase is the 'pancreas' or late arterial phase...PDAC will appear hypovascular and hypoattenuate (appear dark) due to the dense stromal reaction, while neuroendocrine tumors are hypervascular and hyperattenuate (appear bright)." - Fischer's Mastery of Surgery, 8th ed.

Pre-procedure Screening Checklist

Before administering IV iodinated contrast:
  • Empty stomach (fasting ≥6 hours)
  • Previous contrast reactions?
  • Renal function: serum creatinine, eGFR (risk of contrast-induced nephropathy)
  • Diabetes (especially if on metformin - hold for 48 hours post-contrast)
  • Thyroid disease (iodinated contrast can trigger hyperthyroidism)
  • Pregnancy or breastfeeding
  • Known allergies (prior premedication if previous moderate/severe reaction)

CT Abdomen Contrast vs Triple Phase - Summary

FeatureCT Abdomen with ContrastCT Abdomen Triple Phase
PhasesUsually portal venous onlyArterial + portal venous + delayed
RadiationStandard2-3x higher
Best forGeneral abdominal pathology, stagingLiver lesion characterization, HCC, PNETs
Key strengthEfficient, lower doseLesion vascularity profiling
Common useRoutine oncology surveillance, bowel/peritoneal diseaseHCC diagnosis, FNH vs adenoma, hypervascular mets

Sources:
This is a shared conversation. Sign in to Orris to start your own chat.